Achieve Life Sciences, Inc. (ACHV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 197.66M USD | Liabilities, Current |
| Cash and equivalents | 47.96M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 139.34M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $197.66M | $47.96M | $139.34M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $11.83M | $28.08M | $1.19M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $9.08M | $20.93M | $15.47M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.73M | $31.93M | $16.18M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.57M | $51.87M | $3.52M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.13M | $13.02M | $10.23M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.68M | $12.75M | $21.61M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.72M | $9.54M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $13.70M | $14.76M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $20.57M | $66.40M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $20.81M | $15.55M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $4.08M | $19.92M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $3.45M | $25.07M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $20.30M | $16.51M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.60M | $24.77M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.92M | $18.20M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.36M | $29.38M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $4.01M | $36.34M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.55M | $43.02M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $3.08M | $33.31M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.67M | $42.00M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.52M | $29.64M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.94M | $35.85M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $1.85M | $22.39M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $1.81M | $12.11M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.54M | $12.16M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.87M | $16.66M | (m) | $8.00K | (m) | (m) |
| 2019-09-30 | (m) | $3.14M | $7.38M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.99M | $10.45M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $4.00M | $7.32M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $3.27M | $9.52M | (m) | $7.00K | (m) | (m) |
| 2018-09-30 | (m) | $2.96M | $11.76M | (m) | $25.00K | (m) | (m) |
| 2018-06-30 | (m) | $2.76M | $15.28M | (m) | $124.00K | (m) | (m) |
| 2018-03-31 | (m) | $2.32M | $4.17M | (m) | $7.00K | (m) | (m) |
| 2017-12-31 | (m) | $2.01M | $5.28M | (m) | $9.00K | (m) | (m) |
| 2017-09-30 | (m) | $2.33M | $8.02M | (m) | $70.00K | (m) | (m) |
| 2017-06-30 | (m) | $1.75M | $13.92M | (m) | $241.00K | (m) | (m) |
| 2017-03-31 | $16.69M | $1.98M | $15.69M | $760.00K | $237.00K | (m) | 8.43× |
| 2016-12-31 | $25.94M | $8.46M | $15.23M | $10.23M | $478.00K | (m) | 3.07× |
| 2016-09-30 | (m) | $10.59M | $11.80M | $12.76M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $13.87M | $10.58M | $29.15M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $14.53M | $18.91M | $27.20M | (m) | (m) | (m) |
| 2015-12-31 | $55.20M | $20.66M | $34.31M | $20.88M | $14.00K | (m) | 2.67× |
| 2015-09-30 | (m) | $29.35M | $42.48M | (m) | $13.00K | (m) | (m) |
| 2015-06-30 | (m) | $35.03M | $48.00M | (m) | $149.00K | (m) | (m) |
| 2015-03-31 | (m) | $16.24M | $25.28M | (m) | $1.56M | (m) | (m) |
| 2014-12-31 | (m) | $22.22M | $27.90M | (m) | $5.68M | (m) | (m) |
| 2014-09-30 | (m) | $20.93M | $48.95M | (m) | $4.83M | (m) | (m) |
| 2014-06-30 | (m) | $20.17M | $40.61M | (m) | $4.95M | (m) | (m) |
| 2014-03-31 | (m) | $16.90M | $28.63M | (m) | $8.61M | (m) | (m) |
| 2013-12-31 | (m) | $14.93M | $14.59M | (m) | $8.66M | (m) | (m) |
| 2013-09-30 | (m) | $14.37M | $12.95M | (m) | $9.92M | (m) | (m) |
| 2013-06-30 | (m) | $12.72M | $18.75M | (m) | $6.44M | (m) | (m) |
| 2013-03-31 | (m) | $11.00M | $18.63M | (m) | $5.16M | (m) | (m) |
| 2012-12-31 | (m) | $11.56M | $18.07M | (m) | $714.00K | (m) | (m) |
| 2012-09-30 | (m) | $21.67M | $11.36M | (m) | $1.14M | (m) | (m) |
| 2012-06-30 | (m) | $27.36M | $13.84M | (m) | $956.00K | (m) | (m) |
| 2012-03-31 | (m) | $30.95M | $56.85M | (m) | $774.00K | (m) | (m) |
| 2011-12-31 | (m) | $30.79M | $28.52M | (m) | $812.00K | (m) | (m) |
| 2011-09-30 | (m) | $19.12M | $15.72M | (m) | $987.00K | (m) | (m) |
| 2011-06-30 | (m) | $27.86M | $20.88M | (m) | $1.50M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $7.00M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $27.48M | $23.53M | (m) | $1.22M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $11.78M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $33.01M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $62.05M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $7.62M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |